Rallybio (NASDAQ:RLYB – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Rallybio to similar businesses based on the strength of its risk, valuation, analyst recommendations, earnings, profitability, dividends and institutional ownership.
Volatility and Risk
Rallybio has a beta of -0.73, indicating that its stock price is 173% less volatile than the S&P 500. Comparatively, Rallybio’s rivals have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.
Insider & Institutional Ownership
90.3% of Rallybio shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Rallybio and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Rallybio | $860,000.00 | -$8.98 million | -3.63 |
| Rallybio Competitors | $717.36 million | $12.10 million | -14.88 |
Rallybio’s rivals have higher revenue and earnings than Rallybio. Rallybio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of recent recommendations for Rallybio and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rallybio | 1 | 0 | 0 | 0 | 1.00 |
| Rallybio Competitors | 9858 | 15137 | 45528 | 1590 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 99.43%. Given Rallybio’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Rallybio has less favorable growth aspects than its rivals.
Profitability
This table compares Rallybio and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rallybio | -911.07% | -31.44% | -29.89% |
| Rallybio Competitors | -12,285.98% | -196.04% | -30.61% |
Summary
Rallybio rivals beat Rallybio on 8 of the 13 factors compared.
Rallybio Company Profile
Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets. Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}